• Building a team to validate targets for Korro's ADAR-mediated RNA editing platform, with a focus on targets involved in liver disease.

• Created the bioanalytical function within an early-stage company; hired and managed a team of 5, including 2 Senior Scientists.• Supported the advancement of Shielded Living Therapeutics, a complex cell therapy platform utilizing genetically engineered cells to express therapeutic proteins and enzymes, encapsulated within a small molecule-conjugated biomaterial to resist immune response. • Broadly responsible for pre-clinical assay development, manufacturing release assays, and clinical assays, working closely with colleagues in cross-functional program teams.• Supported potency assay development in a wide range of therapeutic areas, including hemophilia, lysosomal diseases (MPS I, Fabry), and Type 1 diabetes.• Managed external CRO resources for assay development and qualification to support GLP toxicity studies.• Built a sample analysis request system to serve research teams company-wide, delivering timely, impactful data to guide decision-making in pre-clinical, platform, and process development.• Participated in pre-IND meetings with FDA and scientific advice meetings with MHRA.• Wrote sections of successful IND & CTA submissions, including CMC (Module 3), nonclinical study reports (Module 4), and time-sensitive responses to information requests.• Transferred potency assays and specifications to contract manufacturer and oversaw GMP release of drug product, resulting in the successful dosing of the company’s first ever patients.

• Wrote business plan together with business school colleagues and established this unique company specializing in the management of bed bugs in multi-unit residences, with a focus on training and inspections.• Built financial models and developed pricing of services, resulting in numerous successful bids for client properties of up to 200 apartments each, and currently serving over 2,500 units.• Managed cash flow, payroll, invoicing, corporate tax filings, insurance, and state licensing.

• Built and led the in vitro biology function as a virtual lab, including: biochemical & cell-based assays, biomarker development, and 3D in vitro models of non-alcoholic steatohepatitis (NASH).• Directed pre-clinical studies for small molecule candidates to treat progressive non-viral liver diseases, including NASH and cholestatic disorders.• Drove evaluation and validation of new targets and signaling pathways in NASH.• Contracted and managed relationships with CROs and academic collaborators.• Performed scientific due diligence on potential partnerships and acquisitions.• Evaluated the scientific merit of Investigator-Initiated Research proposals.• Attended international liver conferences to gather competitive intelligence on NASH research and clinical developments.

• Managed cell biology & assay development functions for pre-clinical programs company-wide.• Built research capabilities within new lab space of an early start-up.• Managed research associates and interfaced with core functional groups across the company.• Coordinated the execution of numerous projects performed at CROs.• Devised and conducted in vitro efficacy assays for product candidates (small molecules, biologics, and induced pluripotent stem cell (iPSC)-derived cellular therapies), in diverse disease areas such as cardiac regeneration, muscular dystrophy (DMD), Type I diabetes and other autoimmune disorders.• Prepared research study protocols and reports in support of an IND application.• Served as liaison with academic postdoctoral fellows under sponsored research agreements.• Worked with Business Development to perform market research for muscle disease indications, apply for non-dilutive funding, and assess KOLs, who were offered consulting contracts.

• Investigated various business models, performing market research and building financial models to support a recommended approach for commercializing marine compounds.• 1st Prize at the UC San Diego Triton Innovation Pitch Competition.

• Utilized industry and scientific knowledge to assess technical risk of companies pitching to the fund.• Conducted extensive due diligence on a life science startup and successfully presented recommendation to the professional Investment Committee, resulting in the fund’s first ever investment.

• Secured resources from multiple departments to support research goals, engaged scientists of various disciplines, and introduced a novel technology platform to the company that utilized zebrafish embryos to screen for bioactive compounds among a large library of natural products.• Performed cheminformatic analysis of hits, including investigation of structure-activity relationship.• Drove collaborations with internal and external investigators to validate MOA predictions based on phenotypic similarity and transcriptional profiling.